389 related articles for article (PubMed ID: 14636486)
1. Treatments for spasticity and pain in multiple sclerosis: a systematic review.
Beard S; Hunn A; Wight J
Health Technol Assess; 2003; 7(40):iii, ix-x, 1-111. PubMed ID: 14636486
[TBL] [Abstract][Full Text] [Related]
2. Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: a systematic review.
Paisley S; Beard S; Hunn A; Wight J
Mult Scler; 2002 Aug; 8(4):319-29. PubMed ID: 12166503
[TBL] [Abstract][Full Text] [Related]
3. A benefit-risk assessment of baclofen in severe spinal spasticity.
Dario A; Tomei G
Drug Saf; 2004; 27(11):799-818. PubMed ID: 15350152
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.
Otero-Romero S; Sastre-Garriga J; Comi G; Hartung HP; Soelberg Sørensen P; Thompson AJ; Vermersch P; Gold R; Montalban X
Mult Scler; 2016 Oct; 22(11):1386-1396. PubMed ID: 27207462
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review.
Chou R; Peterson K; Helfand M
J Pain Symptom Manage; 2004 Aug; 28(2):140-75. PubMed ID: 15276195
[TBL] [Abstract][Full Text] [Related]
6. Functional benefits and cost/benefit analysis of continuous intrathecal baclofen infusion for the management of severe spasticity.
Sampson FC; Hayward A; Evans G; Morton R; Collett B
J Neurosurg; 2002 Jun; 96(6):1052-7. PubMed ID: 12066906
[TBL] [Abstract][Full Text] [Related]
7. Anti-spasticity agents for multiple sclerosis.
Shakespeare DT; Boggild M; Young C
Cochrane Database Syst Rev; 2003; (4):CD001332. PubMed ID: 14583932
[TBL] [Abstract][Full Text] [Related]
8. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis.
Eyssette M; Rohmer F; Serratrice G; Warter JM; Boisson D
Curr Med Res Opin; 1988; 10(10):699-708. PubMed ID: 3286128
[TBL] [Abstract][Full Text] [Related]
9. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam.
Groves L; Shellenberger MK; Davis CS
Adv Ther; 1998; 15(4):241-51. PubMed ID: 10186943
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological interventions for spasticity following spinal cord injury: results of a Cochrane systematic review.
Taricco M; Pagliacci MC; Telaro E; Adone R
Eura Medicophys; 2006 Mar; 42(1):5-15. PubMed ID: 16565680
[TBL] [Abstract][Full Text] [Related]
11. A mixed treatment comparison on efficacy and safety of treatments for spasticity caused by multiple sclerosis: a systematic review and network meta-analysis.
Fu X; Wang Y; Wang C; Wu H; Li J; Li M; Ma Q; Yang W
Clin Rehabil; 2018 Jun; 32(6):713-721. PubMed ID: 29582713
[TBL] [Abstract][Full Text] [Related]
12. Cost analysis of the treatment of severe spinal spasticity with a continuous intrathecal baclofen infusion system.
Postma TJ; Oenema D; Terpstra S; Bouma J; Kuipers-Upmeijer H; Staal MJ; Middel BJ
Pharmacoeconomics; 1999 Apr; 15(4):395-404. PubMed ID: 10537958
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness comparison of tizanidine and baclofen in the management of spasticity.
Rushton DN; Lloyd AC; Anderson PM
Pharmacoeconomics; 2002; 20(12):827-37. PubMed ID: 12236804
[TBL] [Abstract][Full Text] [Related]
14. Anti-spasticity agents for multiple sclerosis.
Shakespeare DT; Boggild M; Young C
Cochrane Database Syst Rev; 2001; (4):CD001332. PubMed ID: 11687107
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of intrathecal baclofen therapy for the treatment of severe spasticity associated with cerebral palsy.
de Lissovoy G; Matza LS; Green H; Werner M; Edgar T
J Child Neurol; 2007 Jan; 22(1):49-59. PubMed ID: 17608306
[TBL] [Abstract][Full Text] [Related]
16. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.
Smolenski C; Muff S; Smolenski-Kautz S
Curr Med Res Opin; 1981; 7(6):374-83. PubMed ID: 7016449
[TBL] [Abstract][Full Text] [Related]
17. Anti-spasticity agents for multiple sclerosis.
Shakespeare DT; Young CA; Boggild M
Cochrane Database Syst Rev; 2000; 2003(4):CD001332. PubMed ID: 11034714
[TBL] [Abstract][Full Text] [Related]
18. Traditional pharmacological treatments for spasticity. Part II: General and regional treatments.
Gracies JM; Nance P; Elovic E; McGuire J; Simpson DM
Muscle Nerve Suppl; 1997; 6():S92-120. PubMed ID: 9826984
[TBL] [Abstract][Full Text] [Related]
19. Outcomes, complications, and dosing of intrathecal baclofen in the treatment of multiple sclerosis: a systematic review.
Cozzi FM; Zuckerman D; Sacknovitz A; Gozum N; Syal A; Danisi F; Sukul V
Neurosurg Focus; 2024 Jun; 56(6):E14. PubMed ID: 38823049
[TBL] [Abstract][Full Text] [Related]
20. Interventions for managing skeletal muscle spasticity following traumatic brain injury.
Synnot A; Chau M; Pitt V; O'Connor D; Gruen RL; Wasiak J; Clavisi O; Pattuwage L; Phillips K
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD008929. PubMed ID: 29165784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
